Product nameAnti-RanGAP1 antibody
See all RanGAP1 primary antibodies
DescriptionRabbit polyclonal to RanGAP1
Tested applicationsSuitable for: IP, WB, IHC-Pmore details
Species reactivityReacts with: Human
Synthetic peptide within Human RanGAP1 aa 100-150. The exact sequence is proprietary. NP_002874.1
Database link: P46060
- WB: HeLa, HEK-293T, Jurkat, TCMK-1 and NIH/3T3 whole cell lysates. IP: HeLa whole cell lysate. IHC-P: Human prostate carcinoma tissue.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
pH 7 to 8
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab245543 was affinity purified using an epitope specific to RanGAP1 immobilized on solid support.
Our Abpromise guarantee covers the use of ab245543 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at 2-10 µg/mg of lysate.|
|WB||1/2000 - 1/10000. Predicted molecular weight: 64 kDa.|
|IHC-P||1/500 - 1/2000. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.|
FunctionGTPase activator for the nuclear Ras-related regulatory protein Ran, converting it to the putatively inactive GDP-bound state.
Tissue specificityHighly expressed in brain, thymus and testis.
Sequence similaritiesBelongs to the RNA1 family.
Contains 6 LRR (leucine-rich) repeats.
modificationsPhosphorylated occurs before nuclear envelope breakdown and continues throughout mitosis. Phosphorylated by the M-phase kinase cyclin B/Cdk1, in vitro. Differential timimg of dephosphorylation occurs during phases of mitosis. The phosphorylated form remains associated with RANBP2/NUP358 and the SUMO E2-conjugating enzyme, UBC9, on nuclear pore complex (NPC) diassembly and during mitosis.
Sumoylated with SUMO1. Sumoylation is necessary for targeting to the nuclear envelope (NE), and for association with mitotic spindles and kinetochores during mitosis. Also required for interaction with RANBP2 and is mediated by UBC9.
Cellular localizationCytoplasm. Nucleus membrane. Chromosome, centromere, kinetochore. Cytoplasm, cytoskeleton, spindle pole. Cytoplasmic during interphase. Targeted to the nuclear rim after sumoylation. During mitosis, associates with mitotic spindles. Association with kinetochores appears soon after nuclear envelope breakdown and persists until late anaphase. Mitotic location also requires sumoylation.
- Information by UniProt
- Fug 1 antibody
- Fug1 antibody
- GTPase-activating protein, RAN, 1 antibody
All lanes : Anti-RanGAP1 antibody (ab245543) at 0.1 µg/ml
Lane 1 : HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate
Lane 2 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate
Lane 3 : Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate
Lane 4 : TCMK-1 (mouse kidney epithelial cell line) whole cell lysate
Lane 5 : NIH/3T3 (mouse embryo fibroblast cell line) whole cell lysate
Lysates/proteins at 50 µg per lane.
Developed using the ECL technique.
Predicted band size: 64 kDa
Exposure time: 30 seconds
RanGAP1 was immunoprecipitated from HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate (0.5 or 1 mg for IP, 20% of IP loaded) with ab245543 at 6 µg/reaction. Western blot was performed from the immunoprecipitate using ab245543 at 0.4 µg/ml.
Lane 1: ab245543 IP in HeLa whole cell lysate.
Lane 2: Control IgG IP in HeLa whole cell lysate.
Detection: Chemiluminescence with exposure time of 30 seconds.
Lysates prepared in NETN buffer.
Formalin-fixed, paraffin-embedded human prostate carcinoma tissue stained for RanGAP1 using ab245543 at 1/1000 dilution in immunohistochemical analysis. Detection: DAB staining.
ab245543 has not yet been referenced specifically in any publications.